[go: up one dir, main page]

GT200300170A - Composiciones farmaceuticas de farmacos semiordenados y polimeros - Google Patents

Composiciones farmaceuticas de farmacos semiordenados y polimeros

Info

Publication number
GT200300170A
GT200300170A GT200300170A GT200300170A GT200300170A GT 200300170 A GT200300170 A GT 200300170A GT 200300170 A GT200300170 A GT 200300170A GT 200300170 A GT200300170 A GT 200300170A GT 200300170 A GT200300170 A GT 200300170A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical compositions
semiordened
polymer drugs
polymer
solubility
Prior art date
Application number
GT200300170A
Other languages
English (en)
Inventor
Walter Christian Babcock
William Brett Caldwell
Marshall David Crew
Dwayne Thomas Friesen
Daniel Tod Smithey
Ravi Mysore Shanker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31715934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200300170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200300170A publication Critical patent/GT200300170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS DE UN FARMACO EN UN ESTADO SEMIORDENADO Y A UN POLIMERO QUE MEJORA LA SOLUBILIDAD DEL MISMO POTENCIALIZANDO A LA VEZ SU CONCENTRACION EN UN ENTORNO DE USO. TODO LO ANTERIOR ES DE SUMA UTILIDAD YA QUE SE MEJORAN CONDICIONES DE BAJA SOLUBILIDAD QUE VAN A DETERMINAR UNA BAJA BIODISPONIBILIDAD O ABSORCION IRREGULAR.
GT200300170A 2002-08-12 2003-08-06 Composiciones farmaceuticas de farmacos semiordenados y polimeros GT200300170A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40308702P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
GT200300170A true GT200300170A (es) 2004-05-12

Family

ID=31715934

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300170A GT200300170A (es) 2002-08-12 2003-08-06 Composiciones farmaceuticas de farmacos semiordenados y polimeros

Country Status (24)

Country Link
US (2) US8257739B2 (es)
EP (2) EP1530457B1 (es)
JP (1) JP2006500349A (es)
CN (1) CN1681479A (es)
AR (1) AR040969A1 (es)
AT (1) ATE442130T1 (es)
AU (1) AU2003249474A1 (es)
BR (1) BR0313428A (es)
CA (1) CA2496441C (es)
DE (1) DE60329188D1 (es)
ES (1) ES2333318T3 (es)
GT (1) GT200300170A (es)
IL (1) IL166411A0 (es)
MX (1) MXPA05000977A (es)
NO (1) NO20050419L (es)
PA (1) PA8579801A1 (es)
PE (1) PE20040865A1 (es)
PL (1) PL375345A1 (es)
PT (1) PT1530457E (es)
RU (1) RU2005103625A (es)
TW (1) TW200406224A (es)
UY (1) UY27929A1 (es)
WO (1) WO2004014342A1 (es)
ZA (1) ZA200500470B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20090142404A1 (en) 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
PT1855652E (pt) 2005-01-28 2016-01-26 Bend Res Inc Secagem de partículas contendo fármacos
PT2043610E (pt) 2006-07-21 2015-10-22 Bend Res Inc Secagem de partículas contendo fármacos
US9101617B2 (en) 2007-04-20 2015-08-11 Daido Chemical Corporation Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
CN103491964A (zh) 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
EP2734190A1 (en) * 2011-07-21 2014-05-28 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
BR112015014065A2 (pt) 2013-03-07 2017-07-11 Dow Global Technologies Llc éter de celulose esterificado, composição, dispersão sólida, forma de dosagem e invólucro de cápsula
WO2014137777A1 (en) 2013-03-07 2014-09-12 Dow Global Technologies Llc Novel esterified cellulose ethers of low viscosity
WO2014137778A1 (en) 2013-03-07 2014-09-12 Dow Global Technologies Llc Novel esterified cellulose ethers of very low viscosity
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
EP2832723B1 (en) * 2013-07-29 2017-02-15 Zentiva, a.s. Stabilised amorphous forms of Saxagliptin
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JPS6314724A (ja) * 1986-07-08 1988-01-21 Tooa Eiyoo Kk プラゾシン製剤
JPH02149518A (ja) * 1988-11-30 1990-06-08 Nikken Chem Co Ltd 経口投与用薬剤
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
JP3345761B2 (ja) * 1993-06-16 2002-11-18 日本特殊陶業株式会社 ヒーター付スパークプラグ及びその製造方法
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5685331A (en) 1994-12-20 1997-11-11 Ac & R Components, Inc. Oil level regulator
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
DE19509806A1 (de) * 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
JPH09309828A (ja) * 1996-03-18 1997-12-02 Eisai Co Ltd 溶解を改善した薬剤組成物
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19637517A1 (de) * 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EA002146B1 (ru) 1997-02-26 2001-12-24 Пфайзер Инк. Производные амида гетероарил-гексановой кислоты, их получение и их применение в качестве селективных ингибиторов связывания mip-1-альфа с его рецептором ccr1
US6126451A (en) 1997-06-02 2000-10-03 Compaq Computer Corporation SCSI connector
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
DE69932920T2 (de) 1998-02-05 2007-02-08 Pfizer Products Inc., Groton Neue dihydroxyhexansäurederivate
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
SK8562002A3 (en) * 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
CA2461890C (en) 2001-09-28 2010-12-14 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US6848693B2 (en) * 2001-11-20 2005-02-01 Actuant Corporation Pseudo four-leg vehicle leveling system with independent leg lock-out
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
EP1694657A1 (en) * 2003-12-09 2006-08-30 Pfizer Inc. Compositions comprising an hiv protease inhibitor

Also Published As

Publication number Publication date
AU2003249474A1 (en) 2004-02-25
EP1530457A1 (en) 2005-05-18
IL166411A0 (en) 2006-01-15
PT1530457E (pt) 2009-11-06
DE60329188D1 (de) 2009-10-22
UY27929A1 (es) 2004-03-31
CN1681479A (zh) 2005-10-12
PL375345A1 (en) 2005-11-28
ZA200500470B (en) 2006-07-26
ES2333318T3 (es) 2010-02-19
EP2111856A3 (en) 2014-09-10
PA8579801A1 (es) 2004-02-16
BR0313428A (pt) 2005-06-28
JP2006500349A (ja) 2006-01-05
WO2004014342A1 (en) 2004-02-19
US20040156905A1 (en) 2004-08-12
US8491933B2 (en) 2013-07-23
AR040969A1 (es) 2005-04-27
CA2496441C (en) 2010-03-16
EP1530457B1 (en) 2009-09-09
RU2005103625A (ru) 2005-08-20
CA2496441A1 (en) 2004-02-19
US8257739B2 (en) 2012-09-04
EP2111856A2 (en) 2009-10-28
NO20050419L (no) 2005-04-04
PE20040865A1 (es) 2004-11-25
MXPA05000977A (es) 2005-05-16
TW200406224A (en) 2004-05-01
US20120322805A1 (en) 2012-12-20
ATE442130T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
GT200300170A (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
AR038372A1 (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido
ATE411007T1 (de) Gegen missbrauch gesicherte darreichungsform
AR045352A1 (es) Forma de dosificacion a prueba de abuso
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
PA8531401A1 (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
UY32503A (es) Formulación pesticida de uso agrícola a base de avermectina y un agente fotoprotector
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
ATE447929T1 (de) Selbstbräuner enthaltend wasserlösliche vitamin b3-komponente und bräunungswirkstoff mit alpha- hydroxycarbonyl-gruppierung
UA99645C2 (ru) Гель, имеющий противовоспалительное и противоаллергическое действие
SV2008002612A (es) Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo
GT200400257A (es) Composicion herbicida
BRPI0510422A (pt) formulação cosmética transparente à base de microemulsões contendo um ácido alfa-hidroxicarboxìlico
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
IS2858B (is) Lyfjasamsetning sem nær yfir melatónín
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
ATE401863T1 (de) Neue viskoelastische zusammensetzung umfassend alginat und vitamin e tpgs oder tpgsa
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
BRPI0416870A (pt) composições anticáncer sinergìticas
EA200702496A1 (ru) Местная композиция, содержащая желатин
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco